Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.908 EUR | -0.10% | -5.07% | +20.38% |
Apr. 11 | Nanoform Finland to Deliver Nanomedicine Technology to Japan | MT |
Apr. 11 | Nanoform Enters Exclusive Partnership with CBC to Bring Best-In-Class Nanomedicine Technology to Japan | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+20.38% | 177M | - | ||
+29.77% | 49.46B | B- | ||
+1.00% | 42.58B | B | ||
+50.47% | 42.49B | A | ||
-5.26% | 29.09B | C | ||
+13.68% | 26.61B | B- | ||
-22.99% | 18.64B | B | ||
+8.22% | 13.16B | B+ | ||
+32.41% | 12.55B | C+ | ||
-1.62% | 11.98B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NANOFH Stock
- Ratings Nanoform Finland Oyj